强生公司宣布RECURE的VAR子研究的急性安全性和有效性结果，评估VAR ULSE平台在治疗心房颤动的PFA手术中

VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE™ Platform in nearly 800 enrolled patientsi

IRVINE, Calif., Sept. 2, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced acute safety and effectiveness results from the VARIPURE substudy of SECURE, evaluating the VARIPULSE™ Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF). The real-world data, presented at the 2025 European Society of Cardiology (ESC) Congress in Madrid, demonstrated a strong safety profile, high acute effectiveness and procedural efficiency within the 791 patients included in this analysis: notably, a 0.6% primary adverse rate with no strokes was reported along with 99.7% acute PVI and high adherence to the recommended ablation workflow.